Isolated Limb Perfusion for Extremity Soft-tissue Sarcomas, In-transit Metastases, and Other Unresectable Tumors: Credits, Debits, and Future Perspectives

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2001 Jun 8

PMID 11389822

Citations 7

Authors

A M Eggermont

T L Ten Hagen

Affiliations

Soon will be listed here.

Abstract

Isolated limb perfusion (ILP) with melphalan is effective against melanoma in-transit metastases but has failed in the treatment of limb-threatening extremity sarcomas. Tumor necrosis factor-alpha (TNF) has changed this situation completely. Now, ILP with TNF + melphalan is a very successful treatment to prevent amputation. In a multicenter European trial, ILP with TNF + melphalan resulted in a 76% response rate and a 71% limb salvage rate in patients with limb-threatening soft-tissue sarcomas, deemed unresectable by independent review committees, leading to approval of TNF in Europe. We have also reported on the success of this regimen against bulky melanomas, multifocal skin cancers, and drug-resistant bony sarcomas. High-dose TNF destructs tumor vasculature, and, most importantly, it enhances tumor-selective drug uptake (ie, melphalan and doxorubicin) by threefold to sixfold. Similar synergy is observed in well-vascularized liver metastases after isolated hepatic perfusion with TNF and melphalan. New (vasoactive) drugs and mechanisms of action and interaction with chemotherapy are in development. ILP is also a promising treatment modality for adenoviral vector-mediated gene therapy. Many clinical phase I/II evaluations in ILP are now underway.

Citing Articles

Soft tissue sarcomas of the upper extremities: Maximizing treatment opportunities and outcomes.

Duran-Moreno J, Kontogeorgakos V, Koumarianou A Oncol Lett. 2019; 18(3):2179-2191.

PMID: 31404317 PMC: 6676724. DOI: 10.3892/ol.2019.10575.

In Vivo Bioorthogonal Chemistry Enables Local Hydrogel and Systemic Pro-Drug To Treat Soft Tissue Sarcoma.

Mejia Oneto J, Khan I, Seebald L, Royzen M ACS Cent Sci. 2016; 2(7):476-82.

PMID: 27504494 PMC: 4965853. DOI: 10.1021/acscentsci.6b00150.

Death receptors as targets for anti-cancer therapy.

Papenfuss K, Cordier S, Walczak H J Cell Mol Med. 2009; 12(6B):2566-85.

PMID: 19210756 PMC: 3828874. DOI: 10.1111/j.1582-4934.2008.00514.x.

Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface.

Gerspach J, Nemeth J, Munkel S, Wajant H, Pfizenmaier K Cancer Immunol Immunother. 2006; 55(12):1590-600.

PMID: 16636812 PMC: 11029883. DOI: 10.1007/s00262-006-0162-6.

Dynamic contrast-enhanced MRI using macromolecular contrast media for monitoring the response to isolated limb perfusion in experimental soft-tissue sarcomas.

Preda A, Wielopolski P, Ten Hagen T, van Vliet M, Veenland J, Ambagtsheer G MAGMA. 2004; 17(3-6):296-302.

PMID: 15480945 DOI: 10.1007/s10334-004-0050-z.

References

Mule J, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A . Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother. 1988; 26(3):202-8. PMC: 11038080. DOI: 10.1007/BF00199930. View

Di Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F . Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer. 1989; 63(12):2551-61. DOI: 10.1002/1097-0142(19890615)63:12<2551::aid-cncr2820631233>3.0.co;2-7. View

CREECH Jr O, Krementz E, RYAN R, WINBLAD J . Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958; 148(4):616-32. PMC: 1450870. DOI: 10.1097/00000658-195810000-00009. View

Kristensen C, Nozue M, Boucher Y, Jain R . Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts. Br J Cancer. 1996; 74(4):533-6. PMC: 2074665. DOI: 10.1038/bjc.1996.397. View

Fraker D, Alexander H, Andrich M, Rosenberg S . Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996; 14(2):479-89. DOI: 10.1200/JCO.1996.14.2.479. View

Fenn N, Horgan K, Johnson R, Hughes L, Mansel R . A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb. Eur J Surg Oncol. 1997; 23(1):6-9. DOI: 10.1016/s0748-7983(97)80134-5. View

Krementz E, Carter R, Sutherland C, Hutton I . Chemotherapy of sarcomas of the limbs by regional perfusion. Ann Surg. 1977; 185(5):555-64. PMC: 1396183. DOI: 10.1097/00000658-197705000-00008. View

de Wilt J, Bout A, Eggermont A, van Tiel S, de Vries M, Ten Hagen T . Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats. Hum Gene Ther. 2001; 12(5):489-502. DOI: 10.1089/104303401300042384. View

Klaase J, Kroon B, van Geel A, Eggermont A, Franklin H, Hart A . Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery. 1994; 115(1):39-45. View

10.

Sijens P, Eggermont A, van Dijk P, Oudkerk M . 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion. NMR Biomed. 1995; 8(5):215-24. DOI: 10.1002/nbm.1940080506. View

11.

Klaase J, Kroon B, Eggermont A, van Geel A, Schraffordt Koops H, Oldhoff J . A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities. Eur J Cancer. 1995; 31A(1):58-63. DOI: 10.1016/0959-8049(94)00372-c. View

12.

Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F . Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 1994; 57(5):656-63. DOI: 10.1002/ijc.2910570508. View

13.

Lienard D, Eggermont A, Koops H, Kroon B, Towse G, Hiemstra S . Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999; 9(5):491-502. DOI: 10.1097/00008390-199910000-00009. View

14.

Di Filippo F, Calabro A, Cavallari A, Carlini S, Buttini G, Moscarelli F . The role of hyperthermic perfusion as a first step in the treatment of soft tissue sarcoma of the extremities. World J Surg. 1988; 12(3):332-9. DOI: 10.1007/BF01655666. View

15.

Omlor G, Gross G, Ecker K, Burger I, FEIFEL G . Optimization of isolated hyperthermic limb perfusion. World J Surg. 1992; 16(6):1117-9. DOI: 10.1007/BF02067073. View

16.

Martijn H, Schraffordt Koops H, Milton G, Nap M, Oosterhuis J, Shaw H . Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer. 1986; 57(10):1923-30. DOI: 10.1002/1097-0142(19860515)57:10<1923::aid-cncr2820571006>3.0.co;2-e. View

17.

STEHLIN Jr J, De Ipolyi P, GIOVANELLA B, Gutierrez A, Anderson R . Soft tissue sarcomas of the extremity. Multidisciplinary therapy employing hyperthermic perfusion. Am J Surg. 1975; 130(6):643-6. DOI: 10.1016/0002-9610(75)90413-4. View

18.

Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N . Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988; 48(8):2179-83. View

19.

Eggermont A, Schraffordt Koops H, Klausner J, Kroon B, Schlag P, Lienard D . Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996; 224(6):756-64; discussion 764-5. PMC: 1235474. DOI: 10.1097/00000658-199612000-00011. View

20.

Manda T, Nishigaki F, Mukumoto S, Masuda K, Nakamura T, Shimomura K . The efficacy of combined treatment with recombinant human tumor necrosis factor-alpha and 5-fluorouracil is dependent on the development of capillaries in tumor. Eur J Cancer. 1990; 26(2):93-9. DOI: 10.1016/0277-5379(90)90289-6. View